Use of hypericum as antidepressant. Valid measure of antidepressant efficacy in primary care is needed
Thornett, A.
Bmj 320(7242): 1141; Author Reply 1143
2000
ISSN/ISBN: 0959-8138
PMID: 10775231
Accession: 047896466
PDF emailed within 1 workday: $29.90
Related References
Walton, M. 2000: Use of hypericum as antidepressant. Naturalistic studies are needed Bmj 320(7242): 1141-2; Author Reply 1143Østergaard, S.ør.D.; Bech, P.; Miskowiak, K.W. 2016: Fewer study participants needed to demonstrate superior antidepressant efficacy when using the Hamilton melancholia subscale (HAM-D₆) as outcome measure Journal of Affective Disorders 190: 842-845
Thompson, C.; Peveler, R.C.; Stephenson, D.; McKendrick, J. 2000: Compliance with antidepressant medication in the treatment of major depressive disorder in primary care: a randomized comparison of fluoxetine and a tricyclic antidepressant American Journal of Psychiatry 157(3): 338-343
Ramalhete, N.; Machado, A.; Serrano, R.; Gomes, E.T.; Mota-Filipe, H.; Silva, O. 2016: Comparative study on the in vivo antidepressant activities of the Portuguese Hypericum foliosum, Hypericum androsaemum and Hypericum perforatum medicinal plants Industrial Crops and Products 82: 29-36
Harrison, P.; Carr, E.; Goldsmith, K.; Young, A.H.; Ashworth, M.; Fennema, D.; Barrett, B.; Zahn, R. 2020: Study protocol for the antidepressant advisor (ADeSS): a decision support system for antidepressant treatment for depression in UK primary care: a feasibility study Bmj Open 10(5): E035905
Simon, G.E. 2002: Evidence review: efficacy and effectiveness of antidepressant treatment in primary care General Hospital Psychiatry 24(4): 213-224
Andrade, C.; Rao, N.Sanjay.Kumar. 2010: How antidepressant drugs act: A primer on neuroplasticity as the eventual mediator of antidepressant efficacy Indian Journal of Psychiatry 52(4): 378-386
Koek, W.; Vacher, B.; Cosi, C.; Assié, M.B.; Patoiseau, J.F.; Pauwels, P.J.; Colpaert, F.C. 2001: 5-HT1A receptor activation and antidepressant-like effects: F 13714 has high efficacy and marked antidepressant potential European Journal of Pharmacology 420(2-3): 103-112
Bechtholt-Gompf, A.J.; Smith, K.L.; John, C.S.; Kang, H.H.; Carlezon, W.A.; Cohen, B.M.; Ongür, D. 2011: CD-1 and Balb/cJ mice do not show enduring antidepressant-like effects of ketamine in tests of acute antidepressant efficacy Psychopharmacology 215(4): 689-695
Sánchez-Mateo, C.C.; Bonkanka, C.X.; Prado, B.; Rabanal, R.M. 2005: Antidepressant properties of some Hypericum canariense L. and Hypericum glandulosum Ait. extracts in the forced swimming test in mice Journal of Ethnopharmacology 97(3): 541-547
Mitchell, P.J.; Redfern, P.H. 1990: Do the pharmaco ethological effects of acute and chronic treatment of rats with antidepressant drugs reveal antidepressant efficacy Journal of Psychopharmacology 4(4): 306
Posternak, M.A.; Zimmerman, M. 2007: Therapeutic effect of follow-up assessments on antidepressant and placebo response rates in antidepressant efficacy trials: meta-analysis British Journal of Psychiatry: the Journal of Mental Science 190: 287-292
Kravitz, H.M.; Fogg, L.; Fawcett, J.; Edwards, J. 1990: Antidepressant or antianxiety? a study of the efficacy of antidepressant medication Psychiatry Research 32(2): 141-149
Silva Almodóvar, A.; Nguyen, D.; Nahata, M.C. 2022: Evidence Needed for Efficacy of Antidepressant Medications Among Patients with Rheumatoid Arthritis Annals of PharmacoTherapy 56(9): 1065-1075
Citrome, L. 2012: Vilazodone for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? International Journal of Clinical Practice 66(4): 356-368
Citrome, L. 2013: Levomilnacipran for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant--what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? International Journal of Clinical Practice 67(11): 1089-1104
Citrome, L. 2014: Vortioxetine for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? International Journal of Clinical Practice 68(1): 60-82
Citrome, L. 2012: Vilazodone for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant ― what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? International Journal of Clinical Practice (Esher) 66(4): 356-368
Glanger, M.R.; Peterson, G.; Abraham, A. 2021: Examining antidepressant use in palliative care patients by risk of antidepressant discontinuation syndrome Internal Medicine Journal 51(5): 793-796
Mak, A.D.P.; Neggers, S.F.W.; Leung, O.N.W.; Chu, W.C.W.; Ho, J.Y.M.; Chou, I.W.Y.; Chan, S.S.M.; Lam, L.C.W.; Lee, S. 2021: Antidepressant efficacy of low-frequency repetitive transcranial magnetic stimulation in antidepressant-nonresponding bipolar depression: a single-blind randomized sham-controlled trial International Journal of Bipolar Disorders 9(1): 40